Lapatinib is an oral, small-molecule, reversible tyrosine kinase inhibitor that dually targets the epidermal growth factor receptor (EGFR/HER1) and human epidermal growth factor receptor 2 (HER2/ERBB2), used in combination with other agents for HER2-positive breast cancer.